Jane Street
SYRE icon

Jane Street’s Spyre Therapeutics SYRE Stock Holding History

Jane Street’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Buy
+21,300
New +$1.55M ﹤0.01% 5268

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jane Street's SYRE Position: Q2 2026 in Review

Jane Street opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 2,909 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #9534 among its holdings. This is a return to the name: Jane Street previously reported a position in SYRE as recently as Q3 2025.

Jane Street first reported a position in SYRE in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.61M in Q3 2025. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Jane Street held 2,909 shares of Spyre Therapeutics worth $258K as of Q2 2026.
  • Spyre Therapeutics was a new Jane Street position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9534 holding.
  • Jane Street first reported a position in Spyre Therapeutics in Q2 2020 and has held it in 9 quarters since.
  • Jane Street's Spyre Therapeutics position peaked at $1.61M in Q3 2025.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.